Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9449850 | 0.90 | MDM4 (0.51) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL22108945 | 0.90 | MDM4 (0.51) | MDM4TP53MDM2BACE1CASP3 | |
| SCHEMBL5969952 | 0.88 | MDM4 (0.54) | MDM4TP53MDM2BACE1CASP3 | |
| SCHEMBL29793991 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2BACE1CASP3 | |
| SCHEMBL3309050 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2BACE1CASP3 | |
| SCHEMBL24899366 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL29423449 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2BACE1CASP3 | |
| SCHEMBL2367138 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2BACE1CASP3 | |
| SCHEMBL31370735 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2BACE1CASP3 | |
| SCHEMBL24899428 | 0.86 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | MDM4 3502/4885TP53 1148/4885MDM2 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.